You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Claims for Patent: 5,324,514

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,324,514

Title:	Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
Abstract:	Disclosed are gastric acid-resistant polymer-coated digestive enzymes/ursodeoxycholate compositions, process for their preparations and methods of treating digestive disorders, treating impaired liver function, treating cystic fibrosis, regulating the absorption of dietary cholesterol, and for dissolving gallstones by administering the compositions to a mammal in need of such treatment.
Inventor(s):	Sipos; Tibor (Lebanon, NJ)
Assignee:	Digestive Care Inc. (Lebanon, NJ)
Application Number:	08/104,655
Patent Claims:	1. A digestive enzyme/bile salt composition for the treatment of digestive enzyme/bile salt deficiency of mammals comprising, by weight per weight percentages based on the total weight of the composition: a) from about 71 to about 90.0% of a concentrate of an enzyme selected from the group consisting of pancreatic proteases, lipases, nucleases and amylases; b) from about 0.3 to about 13% of a bile salt in powder form; c) from about 0.8 to about 5% of a buffering agent consisting of anhydrous sodium carbonate, sodium bicarbonate, potassium carbonate or potassium bicarbonate in combination with about 0.8 to about 1.5% tromethamine, diethanolamine or triethanolamine; d) from about 0.9 to about 16% of a disintegrant selected from the group consisting of starch, modified starches, microcrystalline cellulose and propylene glycol alginate; e) from about 0.3 to about 19.0% of an adhesive polymer selected from the group consisting of hydroxypropyl cellulose, polyvinylpyrrolidone, cellulose acetate phthalate, methyl cellulose and propylene glycol alginate; and f) from about 7.0 to about 15% of an non-porous, gastric acid-resistant and pharmaceutically acceptable polymer-coating which contains of from about 0.2 to about 2% talc and which is insoluble in the pH range of from about 1.5 to about 5 but is soluble in the pH range of from about 5.5 to about 9. 2. The composition of claim 1 wherein said digestive enzyme is selected from the group consisting of pancreatin, pancrelipase, trypsin, chymotrypsin, chymotrypsin B, pancreatopeptidase, carboxypeptidase A, carboxypeptidase B, glycerol ester hydrolase, phospholipase A2, sterol ester hydrolase, ribonuclease dioxyribonuclease, .alpha.-amylase, papain, chymopapain, bromelain, picin, .beta.-amylase, cellulase and .beta.-galactosidase. 3. The composition of claim 1 wherein the salt component of said bile acid is selected from the group consisting of sodium, potassium, ammonium, tromethamine, ethanolamine, diethanolamine and triethanolamine. 4. The composition of claim 3 wherein said bile salt is selected from the group consisting of ursodeoxycholate, ethyl ester of ursodeoxycholate, propyl ester of ursodeoxycholate, glycyl ursodeoxycholate, tauroursodeoxycholate, N-methylglycyl ursodeoxycholate and N-methyltaurine ursodeoxycholate. 5. A method for treating digestive enzyme/bile salt deficiency in mammals comprising: orally administering a therapeutically effective amount of the composition of claim 1. 6. The method of claim 5 wherein about 0.5 to 1.5 gms of the composition is administered to a digestive enzyme/bile salt deficient patient with each meal three times a day. 7. The method of claim 6 wherein said composition is administered in an acid soluble capsule containing from about 0.2 to about 0.5 grams of microspheres or microtablets. 8. The method of claim 6 wherein said composition is administered admixed with a liquid or a semi-solid food.

Details for Patent 5,324,514

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Discure Medical, Llc	CHYMODIACTIN	chymopapain	For Injection	018663	November 10, 1982	5,324,514	2012-06-22
Discure Medical, Llc	CHYMODIACTIN	chymopapain	For Injection	018663	August 21, 1984	5,324,514	2012-06-22
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc.	COTAZYM	pancrelipase	Capsule, Delayed Release	020580	December 09, 1996	5,324,514	2012-06-22
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	April 30, 2009	5,324,514	2012-06-22
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	June 10, 2011	5,324,514	2012-06-22
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	March 14, 2013	5,324,514	2012-06-22
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 5,324,514

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
United States of America	5578304	⤷ Subscribe
United States of America	5460812	⤷ Subscribe
United States of America	5260074	⤷ Subscribe
European Patent Office	0576938	⤷ Subscribe
Canada	2096002	⤷ Subscribe
Australia	666015	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.